Last updated 16 August 2026 · Originally published 4 June 2019
Ask veterans with PTSD what helps and a lot of them will say cannabis. Ask the trials and you get a different answer.
That disagreement is the most interesting thing about this subject, and it’s worth taking seriously in both directions.
What people report
PTSD is among the most common qualifying conditions in US medical cannabis programmes. Veterans use cannabis at high rates, and when asked why, they describe sleeping through the night, being less permanently on edge, and getting through the day.
This isn’t a handful of anecdotes. A 2021 systematic review gathered eleven studies covering 4,672 people, and found cannabis associated with reduced overall PTSD symptom severity and improved quality of life.[1] A 2024 observational study of 58 UK patients using THC-predominant inhaled cannabis reported improvements in symptom severity, sleep, mood and quality of life at three and six months.[2] Only 34 provided six-month data, though, and almost all had used cannabis before — so it describes experienced users who had already chosen it, not a cross-section of patients.
The reviewers were clear about the limitation: almost all of that evidence came from non-randomised studies without comparators, carrying a high risk of bias. Which is a fair caution, and doesn’t make thousands of people describing the same thing meaningless.
It’s the reason researchers went looking in the first place.
What happened when they looked
In 2019 we reported that the first randomised placebo-controlled trial of smoked cannabis for PTSD had been approved. It published in 2021, and the result was not what the surveys predicted.
Eighty US military veterans with chronic PTSD received one of three smoked cannabis preparations — high-THC, high-CBD, or a balanced mix — or a placebo, over three weeks.[3]
Everyone improved from baseline, on every arm. But none beat placebo. No preparation produced a significant difference in PTSD symptom severity against the dummy.
Note what that does and doesn’t say about CBD specifically. Unlike multiple sclerosis, where a THC-CBD medicine has evidence CBD alone lacks, here nothing separated: the high-THC, high-CBD and balanced preparations all performed alike, which is to say none of them outperformed a placebo cigarette.
And in 2026, a Lancet Psychiatry review of 54 cannabinoid trials across mental and substance-use disorders found no significant benefit for PTSD.[4] That’s the largest assessment yet, and it points the same way.
So why the disagreement?
Several possibilities, and they’re not mutually exclusive.
The placebo response was enormous. Everyone in that trial improved substantially, placebo included — in fact the placebo group improved more than the balanced THC-CBD group. The researchers suggested this reflects how strongly veterans expect cannabis to help. A placebo response that large makes any additional drug effect harder to detect, particularly in a small trial.
Three weeks is not what people are describing. Veterans reporting benefit usually mean months or years of use. A short trial can’t capture that, and participants used less cannabis than they normally would.
Withdrawal may have muddied the baseline. Many participants began after stopping their usual cannabis, and reported moderate withdrawal symptoms. Those eased during treatment across all groups, which may have inflated the apparent improvement from baseline.
And it may be relieving something other than PTSD. If cannabis eases sleep and hypervigilance without shifting the underlying disorder, people would accurately report feeling better while a PTSD severity score barely moves. That would be worth something. It isn’t the same as treatment.
And there may be a real effect the trials aren’t catching. A 2026 study followed 74 recently separated US veterans across 4,307 person-days.[5] More hours spent high were associated with lower perceived stress the following day — and that lower stress was in turn associated with better sleep and fewer PTSD symptoms. That’s one plausible account of the relief veterans describe. But everyone in the study already used cannabis, and an observational design can’t show cannabis caused it.
What can’t be ruled out is that expectation explains a large share of it. That’s uncomfortable, but it’s the honest reading of a trial where the dummy performed as well as the drug.
Where CBD might genuinely fit
There’s one line of research here that’s more promising than the headline, and it isn’t about taking CBD instead of treatment.
CBD appears to assist fear extinction learning — the process by which a frightening association is gradually unlearned. In animal studies it dampens cue-triggered fear responses and makes extinction easier.
That matters because extinction learning is the mechanism underlying exposure therapy, one of the most effective PTSD treatments there is. A pilot randomised trial is testing precisely this: CBD given alongside massed prolonged exposure therapy.[8]
A randomised study of 33 people found that a single 300 mg dose reduced one cognitive-impairment response during traumatic recall — but not most measures of anxiety, alertness or discomfort.[9]
CBD has also now been tested directly. In 2026, 30 people with alcohol use disorder and PTSD or subthreshold PTSD took 600 mg daily or placebo for six weeks. CBD did not outperform placebo for PTSD symptoms.[10] Small, and confined to people with comorbid alcohol problems — but it’s a controlled test of CBD, and it was negative.
So the extinction-learning idea remains a plausible role for CBD: something that might help therapy work rather than replace it. Trials combining CBD with prolonged exposure have been completed, but their results haven’t yet been published.
Nightmares, separately
One encouraging finding involves neither CBD nor cannabis, strictly speaking.
A crossover trial in ten military personnel found nabilone, a synthetic THC-like compound, reduced the frequency and intensity of PTSD-related nightmares.[11] Ten people is not much — but nightmares are among the most distressing PTSD symptoms and among the hardest to treat.
The part that matters most
PTSD is treatable, and the treatments have strong evidence behind them.
Trauma-focused therapies — prolonged exposure, cognitive processing therapy, EMDR — work for a great many people, and the effects last. Certain medications help too. None of it is easy, and all of it is better supported than anything above.
There’s also a specific concern from that trial: a few participants across the active conditions reported treatment-related suicidal ideation. It was too small to establish whether cannabis increased that risk — but in a condition already associated with elevated suicide risk, the finding deserves attention.
The dependence question
This is the risk least often discussed, and it deserves saying plainly.
PTSD is independently associated with elevated odds of daily cannabis use — even after accounting for anxiety, mood disorders and the type of trauma.[6] People with PTSD who use cannabis are at higher risk of developing cannabis use disorder, and that creates a genuine clinical tension: the thing being used to manage symptoms is one the condition makes harder to use moderately.
It also complicates stopping. A study of 104 cannabis-dependent veterans found those with PTSD used considerably more at baseline and declined more slowly after a quit attempt.[7]
None of that means don’t. It means going in aware that something easing your evenings can become its own problem, and that PTSD makes that more likely rather than less.
If you’re considering it
Get proper treatment, alongside or first. Use cannabis alongside evidence-based treatment rather than letting symptom relief become a substitute for recovery.
Tell whoever is treating you. Particularly if you’re on medication for PTSD, depression or sleep.
Know what the evidence is about. The main trial tested smoked cannabis. The one controlled standalone CBD trial was negative, while results from the therapy-adjunct trials are still awaited.
Watch your use, not just your symptoms. If the amount is creeping up, or stopping feels difficult, that’s worth raising rather than managing alone.
Watch for avoidance. PTSD recovery involves approaching things you’d rather not. If cannabis is making it easier to avoid therapy, trauma reminders or ordinary responsibilities, discuss that with whoever is treating you.
If you’re struggling badly, get help now — your GP, a crisis line, or your country’s veterans’ mental health service.
Where this leaves it
A lot of people with PTSD say cannabis helps them. The randomised trials say it doesn’t beat placebo — smoked cannabis in 2021, CBD in 2026, and a review of 54 cannabinoid trials the same year.
Both of those can be true. The trial was short, small and conducted in people whose expectations were running high; what it measured may not be what veterans are describing. But a placebo that performs as well as the drug is a serious finding, not a technicality.
The most promising thread is narrower and better founded: CBD may make exposure therapy work better by helping the brain unlearn fear. That’s being tested now, and it’s a role that supports treatment rather than substituting for it.
And whatever you decide, go in knowing that PTSD makes heavy cannabis use more likely and quitting harder. That’s not a reason to avoid it. It’s a reason to keep an eye on it.
None of this is medical advice. PTSD needs proper care, and if you’re in crisis please contact your local emergency or mental health service.
For more, see our guides to CBD and anxiety and what the research actually shows, or browse Mental Health.
References
- Rehman Y, Saini A, Huang S, et al. Cannabis in the management of PTSD: a systematic review. AIMS Neuroscience. 2021. doi:10.3934/Neuroscience.2021022
- Sultan W, Madiedo A, Moreno-Sanz G. Controlled inhalation of tetrahydrocannabinol-predominant cannabis flos mitigates severity of post-traumatic stress disorder symptoms and improves quality of sleep and general mood: a real-world, observational study. Medical Cannabis and Cannabinoids. 2024;7(1):149–159. doi:10.1159/000540978
- Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLOS One. 2021;16(3):e0246990. doi:10.1371/journal.pone.0246990
- Wilson J, Dobson O, Langcake A, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2026;13(4):304–315. doi:10.1016/S2215-0366(26)00015-5
- Davis J, Saba S, Leightley D, et al. Seeking relief or fueling the fire? Understanding the complex role of cannabis in PTSD, stress, and sleep dysregulation. Psychology of Addictive Behaviors. 2026. doi:10.1037/adb0001097
- Cougle J, Bonn-Miller M, Vujanovic A, Zvolensky M, Hawkins K. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychology of Addictive Behaviors. 2011;25(3):554–558. doi:10.1037/a0023076
- Bonn-Miller M, Moos R, Boden M, et al. The impact of posttraumatic stress disorder on cannabis quit success. American Journal of Drug and Alcohol Abuse. 2015;41(4):339–344. doi:10.3109/00952990.2015.1043209
- Straud CL, Roache JD, Ginsburg BC, et al. Enhancing massed prolonged exposure with cannabidiol to improve posttraumatic stress disorder: design and methodology of a pilot randomized clinical trial. Contemporary Clinical Trials Communications. 2024;38:101270. doi:10.1016/j.conctc.2024.101270
- Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology. 2022;239(5):1499–1507. doi:10.1007/s00213-021-06043-y
- Bogenschutz MP, Blessing E, Dgheim D, et al. Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: tolerability but no evidence for efficacy in two randomized proof-of-concept trials. Alcohol, Clinical and Experimental Research. 2026;50(1):e70212. doi:10.1111/acer.70212
- Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588. doi:10.1016/j.psyneuen.2014.11.002
About this article
Substantially rewritten in August 2026. The original was a 2019 podcast episode description, published before the first randomised trial of cannabis for PTSD had reported. This update covers that trial’s findings, why they diverge so sharply from what patients report, and the CBD-specific research since. The original episode audio remains below.
Podcast: Play in new window | Download
